Wegovy isn’t covered by most insurance plans because insurers and employers treat it as a weight loss drug, and weight loss drugs fall into a category that payers have historically been allowed to exclude. The reasons differ depending on whether you have Medicare, Medicaid, or private insurance through an employer, but cost is the driving force behind nearly all coverage denials.
Medicare Is Legally Banned From Covering It
If you’re on Medicare, the barrier is a federal statute. The Social Security Act specifically excludes “agents when used for anorexia, weight loss, or weight gain” from the definition of a covered Part D drug. This isn’t a decision Medicare administrators made on their own. It’s written into law, and it applies to every anti-obesity medication, not just Wegovy.
There is one notable exception. After the FDA approved Wegovy for a new use, reducing the risk of heart attacks and strokes in people with cardiovascular disease who are also overweight or obese, the Centers for Medicare & Medicaid Services issued guidance that Part D plans could begin covering it for that specific purpose. The catch: you must have established cardiovascular disease, meaning a prior heart attack, prior stroke, or peripheral arterial disease. If you’re prescribed Wegovy purely for weight management, Medicare still cannot cover it regardless of your BMI or other health conditions.
Most Employers Choose Not to Cover It
For people with private insurance through work, the decision sits with your employer. Only about 19% of large firms (those with 200 or more workers) cover GLP-1 drugs like Wegovy for weight loss as of 2025. Coverage is more common at very large companies: 43% of firms with 5,000 or more employees include it. But the majority of employers have opted out entirely.
The reason is straightforward: the costs caught employers off guard. Among companies with 5,000-plus workers, 59% reported that use of these medications was higher than expected, and 66% said covering them had a “significant” impact on their prescription drug spending. Patients typically need to stay on the medication long-term to maintain weight loss, which means the cost doesn’t end after a few months. It compounds year after year.
Some employers tried to offer partial coverage but pulled back. One employer quoted in a KFF survey explained it bluntly: “We exclude weight loss, the entire anti-obesity category. We wanted to leave some, but rebates got dramatically worse. We made the business decision to pull the whole category.” In practical terms, that means even if your company’s plan covered Wegovy last year, it might not this year.
There’s also a prescribing problem employers have noticed. Some focus group participants reported that GLP-1 prescriptions for diabetes in their plans were climbing in ways that didn’t match their employee population, suggesting that some enrollees who wanted the drug for weight loss were being diagnosed with diabetes to get around coverage restrictions.
The Sticker Price Isn’t the Whole Story
Novo Nordisk, the company that makes Wegovy, cut its list price by 35% to 50% in early 2026, bringing it to around $675 a month. That sounds like progress, but what matters to insurers isn’t the list price. It’s the net price they actually pay after rebates and discounts negotiated through pharmacy benefit managers. Experts have noted that list price cuts don’t necessarily translate to lower costs for payers, which means the price reduction alone may not be enough to push more insurers toward covering the drug.
What Plans Require When They Do Cover It
If your insurance does include Wegovy on its formulary, expect hurdles. Most commercial plans that cover it require prior authorization, meaning your doctor has to submit paperwork proving you meet specific criteria before the pharmacy will fill the prescription.
The typical requirements mirror the FDA label: a BMI above 30, or a BMI above 27 with at least one weight-related condition like high blood pressure, type 2 diabetes, or sleep apnea. Some plans go further. A review of commercial health plans found that a few imposed stricter BMI cutoffs than the FDA label requires, only covering patients above a BMI of 30 regardless of other health conditions. Your plan may also require documentation that you’ve tried other weight loss approaches first, like diet and exercise programs or older medications.
Options if You’re Paying Out of Pocket
Novo Nordisk offers a savings card that brings the cost down to as little as $25 per fill, but the maximum savings caps at $100 per month. That helps if your insurance covers the drug but sticks you with a high copay. It’s far less useful if your plan excludes Wegovy entirely and you’re facing the full price. Government insurance beneficiaries (Medicare, Medicaid, Tricare) are not eligible for the savings card at all.
If your employer-sponsored plan doesn’t cover Wegovy, Novo Nordisk suggests having your doctor request coverage directly from your company’s HR department. The manufacturer even provides a sample letter for this purpose. Whether that works depends entirely on your employer’s willingness to revisit their formulary decisions, and given how many companies are actively dropping coverage due to cost, the odds vary widely.
Why Coverage Keeps Shifting
The insurance landscape for Wegovy is unusually unstable. Unlike most prescription drugs, where coverage decisions settle into a steady pattern within a year or two of launch, GLP-1 medications for weight loss are still in flux. Employers are adding and dropping coverage from year to year based on how much their plans actually spent. The Medicare exclusion could change if Congress amends the statute, and several legislative proposals have been introduced, but none have passed. And the cardiovascular exception created a new gray area that Medicare Part D plans are still interpreting differently from one another.
If you were denied coverage, it’s worth checking again each year during open enrollment. Plans update their formularies annually, and the combination of price cuts, new clinical data, and competitive pressure from rival drugs could shift your plan’s position. Your best starting point is your plan’s formulary document, which lists exactly which drugs are covered, under what conditions, and at what cost-sharing tier.